The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.
J. Von Pawel
No relevant relationships to disclose
Z. Papai-Szekely
No relevant relationships to disclose
N. Vinolas
No relevant relationships to disclose
C. Sederholm
No relevant relationships to disclose
M. Klima
No relevant relationships to disclose
D. Desaiah
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. I. Leschinger
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
C. Dittrich
Research Funding - Ludwig Institute for Cancer Research